Oak Asset Management LLC Sells 50 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Oak Asset Management LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,810 shares of the biopharmaceutical company’s stock after selling 50 shares during the quarter. Oak Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,742,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. SteelPeak Wealth LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $385,000. River Street Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 7.0% during the first quarter. River Street Advisors LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $443,000 after purchasing an additional 30 shares during the last quarter. New Mexico Educational Retirement Board grew its holdings in Regeneron Pharmaceuticals by 10.7% during the first quarter. New Mexico Educational Retirement Board now owns 6,200 shares of the biopharmaceutical company’s stock valued at $5,967,000 after purchasing an additional 600 shares during the last quarter. Burns J W & Co. Inc. NY acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $1,001,000. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in Regeneron Pharmaceuticals by 22.0% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 2,365 shares of the biopharmaceutical company’s stock valued at $2,276,000 after purchasing an additional 426 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.0 %

Shares of NASDAQ REGN opened at $1,051.03 on Monday. The stock has a market cap of $115.81 billion, a PE ratio of 31.05, a PEG ratio of 2.17 and a beta of 0.13. The business has a fifty day moving average of $984.27 and a two-hundred day moving average of $951.53. Regeneron Pharmaceuticals, Inc. has a 52-week low of $688.52 and a 52-week high of $1,081.17. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The disclosure for this sale can be found here. Over the last three months, insiders sold 61,971 shares of company stock valued at $61,217,654. 7.48% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on REGN. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target on the stock. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. UBS Group increased their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,027.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.